Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
93
days
First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial
Authors
Yaning Yang; Wenxin Jiang; Guangjian Yang; Weihua Li; Junling Li; Xuezhi Hao; Puyuan Xing; Siyu Lei; Fang Wei; Linyan Tian; Haiyan Xu; Yan WangShow moreShow less
Affiliations
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Centre de Recherche des Cordeliers, Équipe Labellisée par la Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris 75006, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Institut, Villejuif 94805, France; Department of Respiratory Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China; Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing 100021, ChinaShow moreShow less
56
days
A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study
Authors
Huaqiang Zhou; Qing Zhou; Qisen Guo; Wei Guo; Gongyan Chen; Zhe Liu; Yun Fan; Yan Li; Yuh-Min Chen; Kenza Bouras; Laurence Del Frari; Angela Guo; Isabelle Klauck; Benoit Sansas; Li ZhangShow moreShow less
Affiliations
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong Province, China; Shandong Cancer Hospital, Huaiyin District, Jinan, Shandong Province, China; Shanxi Cancer Hospital, China; Harbin Medical University Cancer Hospital, Heilongjiang, China; Beijing Chest Hospital, Capital Medical University, China; Zhejiang Cancer Hospital, Zhejiang Cancer Center, Hangzhou, China; Chongqing Cancer Hospital, 181, Hanyu Road, Shapingba District, Chongqing, China; Clinical Research Center and Chest Department, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan; Pierre Fabre Laboratories, France; Pierre Fabre Laboratories, ChinaShow moreShow less
66
days
Macroscopic on-site evaluation for stratifying the incremental diagnostic benefit of additional sampling during endobronchial ultrasound-guided transbronchial needle aspiration
Authors
Tatsuya Imabayashi; Hiroyuki Hashimoto; Yuki Takahashi; Ikuyo Shionoya; Shun Futamura; Sayaka Uda; Tatsuya Yuba; Chieko Takumi; Shinsaku TokudaShow moreShow less
Affiliations
Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto 605-0981, Japan; Department of Infection Control, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto 605-0981, Japan; Department of Clinical Oncology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto 605-0981, JapanShow moreShow less
95
days
Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis
Authors
Ruolin Gao; ZhenXiang Li; Jie Huang; Jun Zhao; Yan Wang; Qinxiang Guo; Guangchuan Deng; Hua Bai; Xu Yang; Jianchun Duan; Zhijie Wang; Yuyan Wang; Jingjing Wang; Jiachen Xu; Rui Wan; Boyang Sun; Kailun Fei; Zixiao Ma; Jia Zhong; Jie WangShow moreShow less
Affiliations
State Key Laboratory of Molecular Oncology, Beijing Key Laboratory, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan City, 250117, China; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China; Department of Respiratory Medicine, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, TaiYuan, ShanXi 030013, China; Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Tianwen Avenue No. 288, Nan’an District, Chongqing 400010, ChinaShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days